Brief: FDA Grants Fast Track Designation For Ambrx's ARX517
19/07/2023 14:25
July 19 (Reuters) - Ambrx Biopharma Inc AMAM.O :
* FDA GRANTS FAST TRACK DESIGNATION FOR AMBRX’S ARX517 FOR
THE
TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Source text for Eikon: ID:nGNX2wpgyj
Further company coverage: AMAM.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ambrx Biopharma
See all newsU.S. RESEARCH ROUNDUP-Burlington Stores, Carrols Restaurant Group, Mastec
U.S. STOCKS ON THE MOVE-Core & Main, Commercial Metals, Equifax
U.S. STOCKS ON THE MOVE-Toll Brothers, American Eagle Outfitters, Twilio
Wrapup 1: Drugmakers kick off industry conference with two cancer deals
U.S. STOCKS ON THE MOVE-Moderna, Coinbase, Ambrx Biopharma